Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis.
Macroscopic bed recurrence
Propensity score-based matched analysis
Prostate cancer
Salvage radiation therapy
Stereotactic radiotherapy
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
12
08
2021
accepted:
01
02
2022
pubmed:
6
3
2022
medline:
12
4
2022
entrez:
5
3
2022
Statut:
ppublish
Résumé
To assess outcomes between salvage radiation therapy (SRT) with curative intent and stereotactic radiotherapy for macroscopic prostate recurrence (SSRT) after radical prostatectomy (RP). In order to compare these two different options, we compared their outcomes with a propensity score-based matched analysis. Data from 185 patients in seven Italian centres treated for macroscopic prostate bed recurrence after RP were retrospectively collected. To make a comparison between the two treatment groups, propensity matching was applied to create comparable cohorts. After matching, 90 patients in the SRT and SSRT groups were selected (45 in each arm). Kaplan-Meier analysis did not show any significant differences in terms of BRFS and PFS between matched populations (p = 0.08 and p = 0.8, respectively). Multivariate models show that treatment was not associated with BRFS, neither in the whole or matched cohort, with HR of 2.15 (95%CI 0.63-7.25, p = 0.21) and 2.65 (95%CI 0.59-11.97, p = 0.21), respectively. In the matched cohort, lower rate of toxicity was confirmed for patients undergoing SSRT, with acute GI and GU adverse events reported in 4.4 versus 44.4% (p < 0.001) and 28.9 versus 46.7% (p = 0.08) of patients, and late GI and GU adverse events reported in 0 versus 13.3% (p = 0.04) and 6.7 versus 22.2% (p = 0.03) of patients, respectively. Considering the favourable therapeutic ratio of this approach and the lower number of fractions needed, SSRT should be considered as an attractive alternative to conventional SRT in this setting.
Identifiants
pubmed: 35247134
doi: 10.1007/s11547-022-01465-w
pii: 10.1007/s11547-022-01465-w
pmc: PMC8897730
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
449-457Informations de copyright
© 2022. Italian Society of Medical Radiology.
Références
Tyson MD 2nd, Andrews PE, Ferrigni RF et al (2016) Radical prostatectomy trends in the United States: 1998 to 2011. Mayo Clin Proc. 91(1):10–6
doi: 10.1016/j.mayocp.2015.09.018
Buglione M, Noale M, Bruni A et al (2019) Treatment paths for localised prostate cancer in Italy: the results of a multidisciplinary, observational, prospective study (Pros-IT CNR). PLoS One 14(11):e0224151
doi: 10.1371/journal.pone.0224151
Thompson IM, Valicenti RK, Albertsen P et al (2013) Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol 190:441–449
doi: 10.1016/j.juro.2013.05.032
Emmett L, Van Leeuwen PJ, Nandurkar R et al (2017) Treatment outcomes from 68Ga-PSMA PET/CT–informed salvage radiation treatment in men with rising psa after radical prostatectomy: prognostic value of a negative PSMA PET. J Nucl Med. 58(12):1972–1976
doi: 10.2967/jnumed.117.196683
Stephenson AJ, Slawin KM, Bianco FJ Jr et al (2004) Perspectives on the natural history of recurrent prostate cancer after radical prostatectomy, based on the response to salvage radiotherapy. BJU Int 94:1210–1212
doi: 10.1111/j.1464-410X.2004.05217.x
Carrie C, Hasbini A, de Laroche G et al (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration. after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17:747–756
doi: 10.1016/S1470-2045(16)00111-X
Tendulkar RD, Agrawal S, Gao T et al (2016) Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol 34(30):3648–3654
doi: 10.1200/JCO.2016.67.9647
Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035–2041
doi: 10.1200/JCO.2006.08.9607
Ingrosso G, Carosi A, di Cristino D et al (2017) Volumetric image-guided highly conformal radiotherapy of the prostate bed: toxicity analysis. Rep Pract Oncol Radiother Jan-Feb 22(1):64–70
doi: 10.1016/j.rpor.2016.10.006
Nath SK, Sandhu AP, Rose BS et al (2010) Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 78(2):435–441
doi: 10.1016/j.ijrobp.2009.08.023
Bellavita R, Massetti M, Abraha I et al (2012) Conformal postoperative radiotherapy in patients with positive resection margins and/or pT3–4 prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 84(3):e299–e304
doi: 10.1016/j.ijrobp.2012.04.002
Bruni A, Ingrosso G, Trippa F et al (2019) Macroscopic locoregional relapse from prostate cancer: which role for salvage radiotherapy? Clin Transl Oncol. https://doi.org/10.1007/s12094-019-02084-0
doi: 10.1007/s12094-019-02084-0
pubmed: 30868389
Francolini G, Jereczek-Fossa BA, Di Cataldo V, Simontacchi G, Marvaso G, Zerella MA, Gentile P, Bianciardi F, Allegretta S, Detti B, Masi L, Lo Russo M, Livi L (2020) Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series. BJU Int 125(3):417–425
doi: 10.1111/bju.14924
Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer: part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 71(4):630–642
doi: 10.1016/j.eururo.2016.08.002
De Cicco L, Bracelli S (2019) Fiducial markers implantation for prostate image-guided radiotherapy: a report on the transperineal approach. Radiol Med 124(2):132–135
doi: 10.1007/s11547-018-0949-5
U.S. Department of Health and Human Services NIH, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-0614_QuickReference_5x7.pdf . Last accessed February, 27 2020
Ho D, Imai K, King G et al (2011) MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 42(8):1–28
doi: 10.18637/jss.v042.i08
Shipley WU, Seiferheld W, Lukka HR et al (2017) NRG oncology RTOG: Radiation With Or Without Antiandrogen Therapy In Recurrent Prostate Cancer. N Engl J Med. 376(5):417–428
doi: 10.1056/NEJMoa1607529
Goldin GH, Sheets NC, Meyer AM et al (2013) Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy. JAMA Intern Med 173(12):1136–1143
doi: 10.1001/jamainternmed.2013.1020
Spratt DE (2018) Evidence-based risk stratification to guide hormone therapy use with salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 102(3):556–560
doi: 10.1016/j.ijrobp.2018.06.037
Sampath S, Frankel P, Vecchio BD et al (2019) Stereotactic body radiation therapy to the prostate bed: results of a phase 1 dose-escalation trial. Int J Radiat Oncol Biol Phys. 106:537
doi: 10.1016/j.ijrobp.2019.11.005
Afshar-Oromieh A, Zechmann CM, Malcher A et al (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41(1):11–20. https://doi.org/10.1007/s00259-013-2525-5
doi: 10.1007/s00259-013-2525-5
pubmed: 24072344
Perera M, Papa N, Roberts M et al (2019) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77:403
doi: 10.1016/j.eururo.2019.01.049
von Eyben FE, Picchio M, von Eyben R et al (2018) 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus 4:686–693
doi: 10.1016/j.euf.2016.11.002
Barra S, Guarnieri A, di Monale E, Bastia MB, Marcenaro M, Tornari E, Belgioia L, Magrini SM, Ricardi U, Corvò R (2021) Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice. Radiol Med 126(1):142–146
doi: 10.1007/s11547-020-01216-9
Francolini G, Desideri I, Stocchi G, Ciccone LP, Salvestrini V, Garlatti P, Aquilano M, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L (2021) Impact of COVID-19 on workload burden of a complex radiotherapy facility. Radiol Med 126(5):717–721
doi: 10.1007/s11547-021-01338-8
Alongi F, De Bari B, Franco P, Ciammella P, Chekrine T, Livi L, Jereczek-Fossa BA, Filippi AR, AIRO Young and AIRO Prostate cancer Working Group (2013) The PROCAINA (PROstate CAncer INdication Attitudes) project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. Radiol Med 118(4):660–678
doi: 10.1007/s11547-012-0913-8
Jereczek-Fossa BA, Bortolato B, Gerardi MA, Dicuonzo S, Arienti VM, Berlinghieri S, Bracelli S, Buglione M, Caputo M, Catalano G, Cazzaniga LF, De Cicco L, Di Muzio N, Filippone FR, Fodor A, Franceschini D, Frata P, Gottardo S, Ivaldi GB, Laudati A, Magrini SM, Mantero E, Meaglia I, Morlino S, Palazzi M, Piccoli F, Romanelli P, Scorsetti M, Serafini F, Scandolaro L, Valdagni R, Orecchia R, Antognoni P, Lombardy Section of the Italian Society of Oncological Radiotherapy (Associazione Italiana di Radioterapia Oncologica-Lombardia, AIRO-L) (2019) Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy. Radiol Med. 124(4):315–322
doi: 10.1007/s11547-018-0972-6